The Beat AML project integrates molecular, drug response, and clinical data for progress towards individualized therapies for acute myeloid leukemia patients. Dr. Jeffrey Tyner from Oregon Health and Science University describes the collaborative effort.
from Insights & Innovations Blog http://bit.ly/2Du4Pvn